New PrEP modalities and service delivery models are on the horizon, with promising findings from recent clinical trials. Current and potential PrEP-users could soon have access to options beyond, but in addition to, oral PrEP; such as cabotegravir long-acting injectables and the islatravir monthly pill, among other ARV formulations and delivery mechanisms such as implants that are in earlier phases. There is also an entirely new class of HIV treatment, broadly neutralising antibodies (bNAbs), that have recently undergone their first efficacy trial as PrEP.
This e-meeting provided community educators and advocates with a concise summary of existing and future PrEP formulations, and a community-level perspective on strategic advocacy within regulatory frameworks to increase community PrEP access and uptake.
- 13:00-13:05 Welcome and introduction (Gus Cairns, PiE)
- 13:05-13:20 The PrEP pipeline: beyond daily oral TDF/FTC PrEP (Cindra Feuer, AVAC)
- 13:20-13:35 Antibodies and vaccines (Penny Moore, University of the Witwatersrand)
- 13:35-13:50 Community level advocacy and access (Michael Meullbroek & Ferran Pujol, BCN Checkpoint)
- 13:50-14:05 Q&A (Moderated by Will Nutland, PrEPster)
- 14:05-14:25 Moderated discussion (Moderated by Will Nutland, PrEPster)
- 14:25-14:30 Meeting wrap-up (Gus Cairns, PiE)